<DOC>
	<DOC>NCT01979965</DOC>
	<brief_summary>The purpose of this study is to find out whether mitral regurgitation (or a leaky heart valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve after administration of ranolazine.</brief_summary>
	<brief_title>Effect of Ranolazine on Valvular Disease in Patients With Pacemakers</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Ischemic cardiomyopathy AND Moderate or severe mitral regurgitation AND Cardiac resynchronization therapy (CRT) ≥ 3 months prior to enrollment AND Maximal Medical Therapy (ACEInhibitor, beta blocker, aldosterone antagonist, diuretic, aspirin, statin) nonischemic cardiomyopathy active heart failure current ranolazine therapy congenital heart disease mechanical valve prostheses vegetation/endocarditis significant pulmonary disease peripheral vascular disease trivial or mild mitral regurgitation creatinine clearance &lt; 30 mL/min liver cirrhosis strong inhibitors of CYP3A (including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir) strong inducers of CYP3A (including rifampin, rifapentine, phenobarbital, phenytoin, carbamazepine and St.John's wort) Strong Pglycoprotein inhibitors (including cyclosporine, verapamil, and quinidine) Initial QTc interval ≥ 440msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>cardiac resynchronization therapy</keyword>
	<keyword>ranolazine</keyword>
	<keyword>maximal medical therapy</keyword>
	<keyword>ischemic cardiomyopathy</keyword>
</DOC>